|
|
| 23-May-2001 |
Endovasc Brings On Dr. Lorenz Hofmann to Speed Approval of Liprostin |
|
Endovasc Brings On Dr. Lorenz Hofmann to Speed Approval of Liprostin
MONTGOMERY, Texas--(BW HealthWire)--May 23, 2001--Endovasc Ltd. Inc. (OTCBB:ENDV - news) today announced the addition of one of the country's leading consultants in Clinical and Regulatory Affairs for drug development, Lorenz Hofmann, Ph.D. to its clinical regulatory staff.
"The addition of Dr. Hofmann to our staff adds great experience and knowledge to Endovasc's upcoming Phase III Clinical Trial that is scheduled to begin in November," said Dr. David P. Summers, chairman & CEO of Endovasc. "Larry Hofmann was brought on in order to assure our commitment to that deadline."
The Company stated Endovasc's Liprostin(™) Phase III trial will be directed to the treatment of Critical Limb Ischemia, caused by the occlusion of blood vessels in the lower limbs and extremities, preventing oxygenated blood flow to the affected areas. Eventually, the disease deteriorates to gangrene and the only option to save the patient's life is amputation. Liprostin(™) (Prostaglandin E-1) is a powerful vasodilator and angiogenic agent and should aid in the process of keeping the vessels open and receptive to healthy blood flow, and maintain the limb.
Dr. Hofmann has a Ph.D. in Cardiovascular-renal pharmacology and has more than 20 years experience in clinical research at the Director and Associate Director levels with major pharmaceutical and medical device companies including: Ross/Abbott Labs, Adria Labs, Parke-Davis and Schwarz Pharma. Dr. Hofmann's credentials include all areas of product development, clinical research and regulatory affairs, such as medical monitor, Investigational New Drug (IND) applications/New Drug Applications (NDA) project leader, Food & Drug Administration negotiations for 15 INDs, 8 approval NDAs for marketed drugs and several medical devices. "Is it any wonder we selected Dr. Hofmann?" asked Dr. Summers.
Endovasc Ltd. Inc. is a biopharmaceutical/biotech company pioneering liposomal drug delivery technology. The Company's products and processes, which include Liprostin™ (liposome encapsulated PGE-1), NRA (Nicotine Receptor Agonist, angiogenesis agent), stent-coating technology, and a biodegradable/resorbable stent, are covered by patents and trade secrets for competing in a multi-billion dollar market.
The foregoing statements are made under the "Safe Harbor" Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements that involve risks and uncertainties that may not be evident at the time of this release. For more information about Endovasc Ltd. Inc.
Contact:
Endovasc Ltd. Inc.,
Jack Sorbi,
936/448-2222
jack@endovasc.com
www.endovasc.com
|
|
|
|
|
